Revvity, Inc.
RVTYHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeRevvity, Inc. provides health sciences solutions, technologies, and services. At a $17.72B market cap, Revvity, Inc. ranks as a large-cap company within healthcare. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Market Cap
$17.72B
Beta
1.06
P/E (TTM)
75.97
P/E (Fwd)
26.94
EPS (TTM)
$2.09
EPS (Fwd)
$5.89
ROE
3.2%
ROA
2.4%
Cash
$1.02B
Total Debt
$3.34B
Free CF
$605.0M
52W Change
60.6%
Annual Financials
Cash vs Debt
Where RVTY stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, RVTY finished 41.14% above its 150-day moving average ($109.24) and 43.26% above its 200-day moving average ($107.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RVTY overbought or oversold?
At the October 12, 2026 close, RVTY's RSI(14) was 66.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Revvity, Inc. carries $3.34B in total debt against $1.02B in cash reserves — debt is roughly 3.3x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $605.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 3.2%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.4% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.31B to $2.86B.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Revvity, Inc. and its sector.